- Myeloproliferative Neoplasms (MPN)
- Pediatric and/or germline mutation-associated disorders
- Myelodysplastic Syndromes (MDS)
The UMR-1131 focuses its research on two areas:
- Normal and pathological haematopoiesis: emergence, environment and translational research
- Control of RNAs translation and tumor cells
- Targeted therapy
- Chemotherapy
Scientific
- Highlighting of the role of the JAK2V617F mutation in endothelial cells
- Description of the role of specific treatments in the selection of specific subclones in MPN patients
- Description of the role of TP53 mutations in conjunction with JAK2 mutations in hematopoiesis
- Mathematical modelling of hematopoiesis
- Identification of senescence induction as a mechanism of the targeted action of interferon alpha on JAK2V617F-mutated cells
- Preclinical characterization of the selective potential of APR-246 on TP53 mutated MDS/AML cells
Medical
- Demonstration of the clinical efficacy of Interferon alpha (IFNa) in MPN
- Demonstration of the targeted activity of IFNa on JAK2 and CALR mutated MPN cells
- Description of the role of specific treatments in the selection of specific subclones in MPN patients
- In vitro and clinical trials to validate a novel formulation of pegylated interferon alpha
- Identification of a novel potential therapeutic option in MPN : Combination of interferon alpha with arsenic trioxide
- Maslah N, Verger E, Giraudier S, Chea M, Hoffman R, Mascarenhas J, Cassinat B, Kiladjian JJ. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Adv. 2022 May 10;6(9):2813-2823. PMID: 35030630
- Dagher T, Maslah N, Edmond V, Cassinat B, Vainchenker W, Giraudier S, Pasquier F, Verger E, Niwa-Kawakita M, Lallemand-Breitenbach V, Plo I, Kiladjian JJ, Villeval JL, de Thé H. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. J Exp Med. 2021 Feb 1;218(2):e20201268. PMID: 33075130
- Bonnet C, Gou P, Girel S, Bansaye V, Lacout C, Bailly K, Schlagetter MH, Lauret E, Méléard S, Giraudier S. Multistage hematopoietic stem cell regulation in the mouse: A combined biological and mathematical approach. iScience. 2021 Nov 6;24(12):103399. PMID: 34877482
- Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 Mar;7(3):e196-e208. PMID: 32014125
- Maillard L, Sanfilippo S, Domenech C, Kasmi N, Petit L, Jacques S, Delezoide AL, Guimiot F, Eladak S, Moison D, Nicolas N, Rouiller-Fabre V, Pozzi-Godin S, Mennesson B, Brival ML, Letourneur F, Jaffredo T, Chomienne C, Souyri M. CD117hi expression identifies a human fetal hematopoietic stem cell population with high proliferation and self-renewal potential. Haematologica. 2020 Jan 31;105(2):e43-e47. PMID: 31248971
- Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S. Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2020 Jun;105(6):1539-1551. PMID: 31488557
- Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018 Oct 4;8(10):94. PMID: 30287855
- Guadall A, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, El Nemer W, Cassinat B, Kiladjian JJ. Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features. Thromb Haemost. 2018 Sep;118(9):1586-1599. PMID: 30103245
- Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014 Jul 10;371(2):188-9. PMID: 25006741
- Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008 Oct 15;112(8):3065-72. PMID: 18650451
National
European
International
